CRLHealthcare · Diagnostics & ResearchThe 16 Wall Street analysts covering Charles River Laboratories International, Inc. hold a median 12-month price target of $300 — +0.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 83 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Charles River Laboratories International, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (90): The shares have been drifting up relative to others.
Volatility (47): The share price moves around a lot.
Size (12): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CRL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +0.5% from it.
Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Aug 2026 | TD Cowen | Maintains | Buy | $235 → $300 |
| 7 Aug 2026 | Morgan Stanley | Maintains | Overweight | $260 → $300 |
| 6 Aug 2026 | Evercore ISI Group | Maintains | Outperform | $260 → $300 |
| 6 Aug 2026 | JP Morgan | Upgrade | Overweight | $180 → $310 |
| 6 Aug 2026 | RBC Capital | Maintains | Outperform | $215 → $282 |
| 20 July 2026 | CLSA | Downgrade | Hold | $219 |
| 20 July 2026 | CLSA | Downgrade | Hold | — |
| 13 July 2026 | Mizuho | Maintains | Neutral | $192 → $230 |
| 13 July 2026 | Mizuho | Maintains | Neutral | — |
| 9 July 2026 | Morgan Stanley | Maintains | Overweight | — |
| 9 July 2026 | Morgan Stanley | Maintains | Overweight | $220 → $260 |
| 17 June 2026 | Morgan Stanley | Upgrade | Overweight | — |
| 29 May 2026 | CLSA | Upgrade | Outperform | — |
| 8 May 2026 | Barclays | Maintains | Overweight | — |
| 8 May 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 14 Apr 2026 | Barclays | Maintains | Overweight | — |
| 13 Apr 2026 | JP Morgan | Maintains | Neutral | — |
| 25 Feb 2026 | UBS | Maintains | Neutral | — |
| 20 Feb 2026 | Mizuho | Maintains | Neutral | — |
| 20 Feb 2026 | TD Cowen | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CRL appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 Aug 2026, Charles River Laboratories International, Inc. returned +84.5% against +19.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 1% of US stocks
Cheaper than 36% of US stocks
Cheaper than 22% of US stocks
Cheaper than 16% of US stocks
Higher than 23% of US stocks
Higher than 33% of US stocks
Higher than 45% of US stocks
Higher than 72% of US stocks
Higher than 23% of US stocks
Higher than 37% of US stocks
Higher than 71% of US stocks
Higher than 7% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Charles River Laboratories International, Inc. has a market value of $14.2B and an enterprise value of $17.0B.
Revenue in the twelve months to 30 June 2026: $4.0B. The latest quarter shrank 2.7% year on year.
Net income over the same four quarters: −$236.3M, a −5.9% net margin.
Diluted earnings per share, trailing twelve months: $−4.85.
Free cash flow in the twelve months to 30 June 2026: $370.6M, after $211.5M of capital spending.
Charles River Laboratories International, Inc. spent $324.1M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 681.3×; forward P/E: 23.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.41%, paying out 0% of earnings.
Charles River Laboratories International, Inc. employs 18,300 people — $219K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Charles River Laboratories International, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Charles River Laboratories' stock rose 33.3% over the past month, driven by stronger bookings and guidance, though the rally now faces margin pressure and a premium valuation.
Why it matters — A CRL watcher would care because the recent surge raises the question of whether the stock's momentum can be sustained given the competing factors of improved bookings and cost pressures.
Charles River Laboratories shares have risen 88.6% over the past year, driven by Discovery and Safety Assessment returning to organic growth, rising bookings, and new testing initiatives that broaden the company's strategy.
Why it matters — CRL watchers would care because the stock's strong year-over-year performance reflects renewed organic growth and strategic expansion in its testing business.
Charles River Laboratories and Medigen Vaccine Biologics Corp. (MVC) have entered a collaboration to characterize and validate the virus seed bank for MVC's next-generation multivalent enterovirus vaccine. Charles River will use its advanced analytical platforms, including Next-Generation Sequencing (NGS), to support critical Chemistry, Manufacturing, and Controls (CMC) activities for the vaccine program.
Why it matters — The collaboration expands Charles River's role in vaccine development and leverages its NGS and analytical capabilities in a new commercial partnership.
The WSJ reports that an insider CEO is taking a fresh look at Charles River Laboratories. The article examines the CEO's new approach to the company given their insider status.
Why it matters — A CRL watcher would care because an insider CEO's fresh perspective could signal a shift in how the company is being managed and evaluated.
Zacks Investment Research published a piece examining how Charles River's (CRL) revenue from international markets is changing and how that shift could affect Wall Street's forecasts and the company's prospects. The article frames this as a deep dive for investors into the international component of CRL's business.
Why it matters — Because a meaningful portion of Charles River's business comes from global markets, changes in international revenue could influence analyst expectations and the company's outlook.
The 16 Wall Street analysts covering Charles River Laboratories International, Inc. have a median 12-month price target of $300, with estimates ranging from $145 to $318. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 16 analysts covering Charles River Laboratories International, Inc., 13 rate it a Buy, 2 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Charles River Laboratories International, Inc. 83 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Charles River Laboratories International, Inc. ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (90 of 100).
No one can know that. What the data says: the median 12-month target from 16 analysts implies +0.5% from the last close, and Ticker Nerd's factor model ranks Charles River Laboratories International, Inc. 83 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Charles River Laboratories International, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $145 to $318 over the next 12 months.
Charles River Laboratories International, Inc. returned +84.5% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Charles River Laboratories International, Inc. is a global contract research organization that provides drug discovery, non-clinical development, and safety testing services to pharmaceutical, biotechnology, and medical device companies.
The most recent item we track (Zacks Investment Research, 21 Aug 2026): "CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running?". Charles River Laboratories' stock rose 33.3% over the past month, driven by stronger bookings and guidance, though the rally now faces margin pressure and a premium valuation.
Charles River Laboratories International, Inc. is a global contract research organization that provides drug discovery, non-clinical development, and safety testing services to pharmaceutical, biotechnology, and medical device companies. Charles River Laboratories supports clients across the early stages of research and development with research models, discovery and safety assessment services, and manufacturing solutions. Its offerings include laboratory testing, toxicology, microbiology, biologics testing, and specialized support for regulated development workflows. The company serves a broad international customer base across North America, Europe, Asia Pacific, and other regions, helping customers advance therapies through preclinical and quality-control processes. Charles River Laboratories International, Inc. is headquartered in Wilmington, Massachusetts, and remains a key service provider within the healthcare and diagnostics research market.
CEO Ms. Birgit Girshick · 18,300 employees · United States · https://www.criver.com
